Last reviewed · How we verify
Para-Aminosalicylic Acid
Para-Aminosalicylic Acid is a bacteriostatic antibiotic that inhibits the synthesis of folate in bacteria.
Para-Aminosalicylic Acid is a bacteriostatic antibiotic that inhibits the synthesis of folate in bacteria. Used for Tuberculosis.
At a glance
| Generic name | Para-Aminosalicylic Acid |
|---|---|
| Also known as | PAS |
| Sponsor | Beijing Chest Hospital |
| Drug class | Bacteriostatic antibiotic |
| Target | Dihydropteroate synthetase |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
It does this by competitively inhibiting the enzyme dihydropteroate synthetase, which is necessary for the synthesis of tetrahydrofolate. This action prevents the bacteria from producing the necessary nucleotides for DNA synthesis and replication, ultimately leading to the inhibition of bacterial growth.
Approved indications
- Tuberculosis
Common side effects
- Gastrointestinal disturbances
- Neurological effects
Key clinical trials
- Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis (NA)
- Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease (PHASE2, PHASE3)
- Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis. (NA)
- Confirmatory Clinical Study in Active Ulcerative Colitis (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis
- Minocyclin in Ulcerative Colitis as Added on Therapy (PHASE2)
- Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Para-Aminosalicylic Acid CI brief — competitive landscape report
- Para-Aminosalicylic Acid updates RSS · CI watch RSS
- Beijing Chest Hospital portfolio CI